Comprehensive Income (Loss), Net of Tax, Attributable to Parent of Immix Biopharma, Inc. from 31 Dec 2020 to 31 Dec 2024

Taxonomy & unit: us-gaap: USD
Description: Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary: Immix Biopharma, Inc. quarterly and annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD history and change rate from 31 Dec 2020 to 31 Dec 2024.
Immix Biopharma, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 31 Dec 2024 was $5,005,161, a 0.07% decline year-over-year.
Immix Biopharma, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending 31 Dec 2024 was $21,749,098, a 41% decline year-over-year.
Immix Biopharma, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was $21,749,098, a 41% decline from 2023.
Immix Biopharma, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was $15,378,403, a 86% decline from 2022.
Immix Biopharma, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was $8,268,100, a 66% increase from 2021.
Source SEC data: View on sec.gov

Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)

Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)

Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)

Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)

Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)

Immix Biopharma, Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2024	$21,749,098	$5,005,161	-$3,588	-0.07%	01 Oct 2024	31 Dec 2024	10-K	25 Mar 2025	2024	FY
Q3 2024	$21,745,510	$7,074,316	-$2,759,505	-64%	01 Jul 2024	30 Sep 2024	10-Q	12 Nov 2024	2024	Q3
Q2 2024	$18,986,005	$4,365,578	-$787,697	-22%	01 Apr 2024	30 Jun 2024	10-Q	12 Aug 2024	2024	Q2
Q1 2024	$18,198,308	$5,304,043	-$2,819,905	-114%	01 Jan 2024	31 Mar 2024	10-Q	09 May 2024	2024	Q1
Q4 2023	$15,378,403	$5,001,573	-$1,226,702	-32%	01 Oct 2023	31 Dec 2023	10-K	25 Mar 2025	2024	FY
Q3 2023	$14,151,701	$4,314,811	-$2,739,372	-174%	01 Jul 2023	30 Sep 2023	10-Q	12 Nov 2024	2024	Q3
Q2 2023	$11,412,329	$3,577,881	-$1,976,552	-123%	01 Apr 2023	30 Jun 2023	10-Q	12 Aug 2024	2024	Q2
Q1 2023	$9,435,777	$2,484,138	-$1,167,677	-89%	01 Jan 2023	31 Mar 2023	10-Q	09 May 2024	2024	Q1
Q4 2022	$8,268,100	$3,774,871	+$18,978,912	+83%	01 Oct 2022	31 Dec 2022	10-K	29 Mar 2024	2023	FY
Q3 2022	$27,247,012	$1,575,439	-$1,168,655	-287%	01 Jul 2022	30 Sep 2022	10-Q	13 Nov 2023	2023	Q3
Q2 2022	$26,078,357	$1,601,329	-$1,397,389	-685%	01 Apr 2022	30 Jun 2022	10-Q	11 Aug 2023	2023	Q2
Q1 2022	$24,680,968	$1,316,461	-$290,636	-28%	01 Jan 2022	31 Mar 2022	10-Q	12 May 2023	2023	Q1
Q4 2021	$24,390,332	$22,753,783			01 Oct 2021	31 Dec 2021	10-K	27 Mar 2023	2022	FY
Q3 2021		$406,784			01 Jul 2021	30 Sep 2021	10-Q	09 Nov 2022	2022	Q3
Q2 2021		$203,940			01 Apr 2021	30 Jun 2021	10-Q	12 Aug 2022	2022	Q2
Q1 2021		$1,025,825			01 Jan 2021	31 Mar 2021	10-Q	13 May 2022	2022	Q1

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2024	$21,749,098	-$6,370,695	-41%	01 Jan 2024	31 Dec 2024	10-K	25 Mar 2025	2024	FY
2023	$15,378,403	-$7,110,303	-86%	01 Jan 2023	31 Dec 2023	10-K	25 Mar 2025	2024	FY
2022	$8,268,100	+$16,122,232	+66%	01 Jan 2022	31 Dec 2022	10-K	29 Mar 2024	2023	FY
2021	$24,390,332	-$23,306,106	-2150%	01 Jan 2021	31 Dec 2021	10-K	27 Mar 2023	2022	FY
2020	$1,084,226			01 Jan 2020	31 Dec 2020	10-K	28 Mar 2022	2021	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.